Cytomegalovirus DNA Doubling Time for Early Identification of Clinically Significant Infection Episodes in Allogeneic Hematopoietic Stem Cell Transplant Recipients Undergoing Primary Letermovir Prophylaxis: A Multicenter Study

Documenti analoghi

• Reduction in Length of Hospital Stays for Allogeneic Hematopoietic Stem‐Cell Transplantation in the Letermovir Era
  di: Hiroki Hosoi, et al.
  Pubblicazione: (2025)
• Clinically Significant EBV Infection in Allogeneic Stem Cell Transplanted Children Receiving Letermovir as Primary CMV Prophylaxis
  di: Christina Oikonomopoulou, et al.
  Pubblicazione: (2025)
• The Changing Epidemiology of Breakthrough Invasive Fungal Disease in Allogeneic Hematopoietic Stem Cell Transplant Recipients in the Era of Modified‐Release Posaconazole Prophylaxis
  di: Shio Yen Tio, et al.
  Pubblicazione: (2025)
• Resistant/Refractory Cytomegalovirus Retinitis in Solid Organ and Hematopoietic Stem Cell Transplant Recipients: The Cause‐or‐Consequence Dilemma
  di: Renato Pascale, et al.
  Pubblicazione: (2026)
• Real‐World Experience With Maribavir for Treatment of Refractory or Resistant Cytomegalovirus Infection in Hematopoietic Cell Transplant Recipients and Hematologic Malignancy Patients
  di: Marilyne Daher, et al.
  Pubblicazione: (2025)